AAOMS Annual Meeting

The FDA has approved new options for major depressive disorder, schizophrenia, and metastatic non-small cell lung cancer, that clinicians should be aware of.

The FDA has decided to strengthen existing cardiovascular warnings on the labels of prescription non-aspirin nonsteroidal anti-inflammatory drugs.

The FDA has approved new options for the treatment of heart failure and cystic fibrosis, and issued a warning on unapproved prescription ear drops.

The FDA has approved new options for the treatment of heart failure and cystic fibrosis, and issued a warning on unapproved prescription ear drops.

The FDA has approved new options for the treatment of heart failure and cystic fibrosis, and issued a warning on unapproved prescription ear drops.

The FDA finalized a decision determining that partially hydrogenated oils were not generally recognized as safe.

The FDA finalized a decision determining that partially hydrogenated oils were not generally recognized as safe.

The FDA finalized a decision determining that partially hydrogenated oils were not generally recognized as safe.

...

An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.